Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Study: Teens and young adults respond well to learning about familial cancer risk
    • [No author given]
    • FORCE. XRAY. 2022 Oct 11.

    Related:

    Original research:

    Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    • Validation of the modified Chinese Information and Support Needs Questionnaire (ISNQ-C) for daughters of mothers with breast cancer.
    • Fang SY, Chen TC.
    • Palliat Support Care. 2022 Oct 11:1-9. doi: 10.1017/S1478951522001407. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Study: Teens and young adults respond well to learning about familial cancer risk
    • [No author given]
    • FORCE. XRAY. 2022 Oct 11.

    Related:

    Original research:

    Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    • Validation of the modified Chinese Information and Support Needs Questionnaire (ISNQ-C) for daughters of mothers with breast cancer.
    • Fang SY, Chen TC.
    • Palliat Support Care. 2022 Oct 11:1-9. doi: 10.1017/S1478951522001407. Epub ahead of print.

    • A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.
    • Kai M, Kubo M, Shikada S, Hayashi S, Morisaki T, Yamada M, Takao Y, Shimazaki A, Harada Y, Kaneshiro K, Mizuuchi Y, Shindo K, Nakamura M.
    • Surg Case Rep. 2022 Oct 11;8(1):197. doi: 10.1186/s40792-022-01546-y.

    • Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda.
    • Ashi K, Ndom P, Gakwaya A, Makumbi T, Olopade OI, Huo D.
    • Cancer Epidemiol Biomarkers Prev. 2022 Oct 10:EPI-22-0869. doi: 10.1158/1055-9965.EPI-22-0869. Epub ahead of print.

    • Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations.
    • Dietrich M, Ball E, McKenzie A, Vidal G.
    • OncLive. Peer Exchange. 2022 Oct 10.

    • Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
    • Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
    • Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.

    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

    • Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
    • DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group, Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubinski J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR.
    • J Natl Cancer Inst. 2022 Oct 10:djac160. doi: 10.1093/jnci/djac160. Epub ahead of print.

    • Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
    • DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group, Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubinski J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR.
    • J Natl Cancer Inst. 2022 Oct 10:djac160. doi: 10.1093/jnci/djac160. Epub ahead of print.

    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

    • Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    • Bahar-Shany K, Barnabas GD, Deutsch L, Deutsch N, Glick-Saar E, Dominissini D, Sapoznik S, Helpman L, Perri T, Blecher A, Katz G, Yagel I, Rosenblatt O, Shai D, Brandt B, Meyer R, Mohr-Sasson A, Volodarsky-Perel A, Zilberman I, Armon S, Jakobson-Setton A, Eitan R, Kadan Y, Beiner M, Josephy D, Brodsky M, Friedman E, Anafi L, Molchanov Y, Korach J, Geiger T, Levanon K.
    • Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318. Epub ahead of print.

    Related:

    Identifier: NCT03150121: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage (BEDOCA). (ClinicalTrials.gov . Accessed 2022 Oct 10.)

    • LitAlert ~~ GeneLit.com

    • Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    • Bahar-Shany K, Barnabas GD, Deutsch L, Deutsch N, Glick-Saar E, Dominissini D, Sapoznik S, Helpman L, Perri T, Blecher A, Katz G, Yagel I, Rosenblatt O, Shai D, Brandt B, Meyer R, Mohr-Sasson A, Volodarsky-Perel A, Zilberman I, Armon S, Jakobson-Setton A, Eitan R, Kadan Y, Beiner M, Josephy D, Brodsky M, Friedman E, Anafi L, Molchanov Y, Korach J, Geiger T, Levanon K.
    • Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318. Epub ahead of print.

    Related:

    Identifier: NCT03150121: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage (BEDOCA). (ClinicalTrials.gov . Accessed 2022 Oct 10.)

    • Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
    • DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group, Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubinski J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR.
    • J Natl Cancer Inst. 2022 Oct 10:djac160. doi: 10.1093/jnci/djac160. Epub ahead of print.

    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

    • Optical genome mapping identifies clinically relevant genomic rearrangements in prostate cancer biopsy sample.
    • Shim Y, Lee J, Seo J, Park CK, Shin S, Han H, Lee ST, Choi JR, Chung BH, Choi YD.
    • Cancer Cell Int. 2022 Oct 8;22(1):306. doi: 10.1186/s12935-022-02728-2.